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Abstract
Tumor suppressor microRNA-126 (miR-126) is often down-regulated in cancer cells, and its over-
expression is found to inhibit cancer metastasis. To elucidate the mechanism of tumor suppression
by miR-126, we analyzed the proteomic response to miR-126 over-expression in the human
metastatic breast cancer cell line MDA-MB-231. To acquire quantitative, time-resolved
information, we combined two complementary proteomic methods, BONCAT and SILAC. We
discovered a new direct target of miR-126: CD97, a pro-metastatic G-protein-coupled receptor
(GPCR) that has been reported to promote tumor cell invasion, endothelial cell migration and
tumor angiogenesis. This discovery establishes a link between down-regulation of miR-126 and
over-expression of CD97 in cancer, and provides new mechanistic insight into the role of miR-126
in inhibiting both cell-autonomous and non-cell-autonomous cancer progression.
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microRNAs (miRNAs), small noncoding RNAs that regulate gene expression post-
transcriptionally, have been predicted to control more than 60% of all protein-coding genes
in mammals.1 miRNAs play essential roles in many biological processes, including
angiogenesis and tumorigenesis.2, 3 Unsurprisingly, dysregulation of miRNAs has been
observed in various human cancers.3 For example, miR-126, a microRNA involved in
angiogenesis,4 has been reported to exhibit reduced expression in many human cancers.5
miR-126 has been defined as a metastasis suppressor because its over-expression was found
to suppress metastasis of breast cancer cells to lung and bone.6 Substantial effort has been
devoted to understanding the role of miR-126 in suppression of metastasis; however, the
underlying mechanism of regulation remains incompletely understood.
In this study, we investigated the regulatory effects of miR-126 in human breast cancer cells
by combining two complementary methods of proteomic analysis: SILAC and BONCAT.
BONCAT (bioorthogonal noncanonical amino acid tagging) is used to isolate proteins
synthesized within specified time intervals, and provides the temporal resolution needed to
elucidate time-dependent proteomic responses to cellular stimuli.7 Moreover, BONCAT
reduces sample complexity, an important limitation in protein identification by mass
spectrometry (MS), by removing the pre-existing proteome.8–11 To quantify the proteomic
changes observed upon over-expression of miR126, we combined BONCAT with SILAC
(stable isotope labeling by amino acids in cell culture), a widely used method for MS-based
quantitative proteomics.12–12 This approach led us to the discovery that CD97, a pro-
metastatic adhesion G-protein coupled receptor (GPCR), is a direct target of miR-126. This
result sheds new light on the role of miR-126 in tumor suppression.
Results and Discussion
Inducible Expression of miR-126 in Human Breast Cancer Cells
To probe the cellular response to miR-126 expression, we modified the human metastatic
breast cancer cell line MDA-MB-231 by lentiviral transduction with the SparQ™ Cumate
Switch system. The resulting cell line (designated MDA-CuO-miR) is characterized by
constitutive expression of GFP as a selection marker and by cumate-inducible expression13
of a miR-126 precursor (SI Figure S1a). Because endogenous miR-126 is encoded by intron
7 of the epidermal growth-factor-like domain 7 (egfl7) gene,14 we designed the precursor
sequence to include the pre-miR-126 and flanking regions from intron 7 to ensure proper
transcription and processing. Cells were separated on the basis of GFP fluorescence to
obtain cell populations with similar numbers of transgene integrations (SI Figure S2).
We assessed cumate-inducible expression of miR-126 by using the reverse transcriptase
polymerase chain reaction (RT-PCR) (SI Figure S1b). At 2, 8, 24, and 72 h after induction
with various concentrations of cumate, cells were harvested and total RNA was isolated.
Expression of miR-126 increased with induction time; significant over-expression was
apparent 8 h after induction. For proteomic studies, we raised the level of expression of
miR-126 approximately seven-fold by inducing with 300 Hg/mL cumate for 24 h. We
believe such conditions to be relevant to the biology of metastasis; the weakly metastatic
human breast cancer cell line MCF-7 expresses miR-126 at levels approximately three-fold
higher than MDA-MB-23115 and roughly nine-fold higher than more aggressively
metastatic MDA derivatives.6
Combining BONCAT and SILAC
We investigated the effects of miR-126 over-expression on protein synthesis by combining
BONCAT and SILAC (Figure 1). MDA-CuO-miR cells were adapted in SILAC medium
containing either L-lysine (Lys) or [13C6, 15N2]L-lysine (Lys8) for five doubling times to
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ensure near-quantitative incorporation of Lys8 in the “heavy” culture. Expression of
miR-126 was induced in the heavy culture by addition of cumate. A label-swap experiment
was performed to control for any changes in protein expression that might be caused by
isotope-labeling. At 24 h post induction, both cultures were treated with azidohomoalanine
(Aha), a translationally-active methionine analogue that renders proteins susceptible to
tagging with affinity probes via the copper-catalyzed azide-alkyne cycloaddition reaction.16
Cells were incubated with Aha for 4 h, harvested and lysed, and lysates were mixed at equal
protein concentrations. The mixed lysates were treated with an acid-cleavable alkyne-biotin
tag17 to enable affinity enrichment of Aha-labeled proteins for MS analysis.
MS analysis revealed 91 proteins that exhibited significant changes of at least 20% in
expression upon miR-126 induction. To address the possible effects of the inducer, control
experiments were performed in which cumate was added both to MDA-CuO-miR cells and
to a control cell line (MDA-CuO) transduced with empty vector. A set of 33 responsive
proteins was identified by applying two criteria: the protein must 1) be quantified on the
basis of six or more peptide ratio measurements, and 2) exhibit at least a 20% change in
expression with consistent direction of regulation in both sets of experiments described
above (SI Table S1). We imagined that this set of proteins would include some that are
directly regulated by miR-126, and others that are affected indirectly. The most prevalent
mechanism of regulation by human miRNAs involves translational repression as a
consequence of miRNA binding in the 3’-untranslated region (UTR) of the target transcript.1
To identify potential direct targets, we cross-referenced the down-regulated proteins with the
lists of predicted targets of miR-126 obtained from the following resources: MicroCosm,
Target Scan, and microRNA.org, and identified one predicted target, cd97. The fact that
CD97 is an established promoter of tumor metastasis18 made this observation especially
intriguing. Quantitative mass spectrometry, based on 48 independent peptide measurements,
indicated 26% down-regulation of CD97 upon cumate induction of miR-126 (p-value =
6.4×10−7 with the null hypothesis that CD97 is unchanged upon over-expression; SI Figure
S3).
cd97 is a Direct Target of miR-126
We used a luciferase reporter assay to determine whether cd97 is a direct target of miR-126
(Figure 2a). The miR-126 precursor sequence used for MS studies was cloned downstream
of the CMV promoter in expression vector pcDNA™3.1(+) to generate pcDNA™3.1(+)-
miR126. Next, the entire 3’-UTR of cd97 was cloned into the firefly luciferase reporter
construct pMIR-REPORT™ and co-transfected with either pcDNA™3.1(+)-miR126
(miR-126) or pcDNA™3.1(+) (empty vector control) into human embryonic kidney
(HEK293) cells. Positive and negative controls were used to validate the assay: pMIR-
REPORT ™, which contains no 3’-UTR downstream of luciferase; 2miR, which carries two
miR-126 binding sites; and IRS1, which includes the 3’-UTR of insulin receptor substrate-1
(irs1), a known direct target of miR-126.19 As expected, luciferase activity in the reporter
constructs 2miR and IRS1 was reduced by over-expression of miR-126. Notably, cells
bearing the reporter construct containing the cd97 3’-UTR exhibited a ~40% decrease in
luciferase activity, roughly twice the extent of knockdown observed for the known target
irs1 (Figure 2b). These results provide the first experimental evidence that cd97 is a direct
target of miR-126.
To identify possible miR-126 binding sites, we aligned the 3’-UTR of cd97 with the mature
miR-126 sequence by using the microRNA target prediction algorithm RNAhybrid.20 We
found extensive sequence complementarity, including a 5-nucleotide seed-matched site
(Figure 2c). We created several luciferase reporter constructs carrying mutations in the cd97
3’-UTR, and evaluated the effects of miR-126 on expression (Figure 2d). Guided by the
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predicted binding site, we made cd97-ex by removing all 11 interacting nucleotides and
cd97-M3-126 by introducing three point mutations in the predicted binding region. A
control construct, cd97-R1, has three point mutations at a random site that is not predicted to
bind miR-126. To address the possibility that the flanking sequences may produce false-
positive results, we did not use empty vector as the control for miR-126 over-expression.
Instead, we constructed pcDNA™3.1(+)-miR-ex (miR-ex control), which lacks the pre-
miR-126 sequence and leaves the flanking regions intact. Compared to cells expressing the
miR-ex control, cells co-transfected with miR-126 and the luciferase construct containing
the cd97 3’-UTR exhibited a knockdown of approximately 40% in luciferase activity.
Luciferase expression was rescued either by removing the predicted binding site or by
introducing three point mutations within the predicted binding sequence (Figure 2d). In
contrast, mutating three nucleotides at an arbitrary site within the cd97 3’-UTR had little
effect on luciferase activity. These results confirm the binding site for miR-126 in the 3’-
UTR of cd97.
In addition to miR-126, pre-miR-126 contains another known microRNA, miR-126*.
Because it has been shown that miR-126 and miR-126* can suppress expression of the same
target by binding to different sites in the 3’-UTR,21 we wondered whether miR-126* also
targets cd97. In contrast to miR-126, the cd97 3’-UTR does not share strong sequence
complementarity with the seed region of miR-126* (Figure 2e). We constructed three
luciferase reporter constructs: cd97-M3-126* contains three mutations within the predicted,
most favorable interacting region for miR-126*, cd97-M3-126+126* has mutations both in
the binding region predicted for miR-126 and in that predicted for miR-126*, and cd97-M3-
R1+R2 is a control construct with mutations at two random sites. As expected, mutations at
random sites within the 3’-UTR of cd97 did not affect suppression of luciferase activity by
miR-126 (Figure 2f). While mutations in the predicted binding site for miR-126* also had
little effect on the luciferase signal, the additional mutation in the miR-126 binding site
abolished suppression of luciferase activity. These results indicate that miR-126, not
miR-126*, controls expression of cd97.
Implications for the Mechanism of Tumor Suppression by miR-126
Reduced expression of miR-126 is observed in many cancers, identifying it as a putative
tumor suppressor. To better understand its role in cancer metastasis, we investigated the
regulatory effects of miR-126 on protein synthesis in human breast cancer cells, and found
consistent down-regulation of CD97 upon over-expression of miR-126. Further, we
discovered that miR-126 suppresses expression of cd97 by binding directly to its 3’-UTR.
This discovery establishes a link between two welldocumented observations in cancer
biology: the down-regulation of tumor suppressor miR-1266, 19 and the over-expression of
cd97.22–26
CD97 is an adhesion G-protein coupled receptor (GPCR) involved in cell adhesion and
migration.27 Expression levels of CD97 were found to correlate with the in vitro migration
and invasion capacity of many colorectal tumor cell lines.25 Tumor cells at the invasion
front of colorectal and gastric carcinomas exhibited elevated CD97 expression as compared
to other cells within the same tumor.25, 28 Furthermore, over-expression of CD97 has been
shown to stimulate cell motility in vitro and to promote tumor growth in vivo.29 All of these
observations suggest that CD97 plays a role in promoting tumor invasion by stimulating
tumor cell migration. Similar functions have also been reported for a known target of
miR-126, crk.15 Crk is a component of the focal adhesion network, and decreased Crk
expression has been shown to suppress tumor cell migration.15 Furthermore, it has been
reported that miR-126 inhibits gastric cancer metastasis, partially through the down-
regulation of Crk.30 The discovery that miR-126 targets cd97, a pro-metastatic factor that is
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found to be elevated in a majority of gastric carcinomas,22 suggests that miR-126 may
suppress metastasis through down-regulation of both Crk and CD97.
In addition to promoting tumor progression in a cell-autonomous manner, CD97 has also
been shown to function non-cell-autonomously. CD97 stimulates the motility and invasion
of endothelial cells by binding to cell surface integrins to promote angiogenesis,31 an
essential process in cancer metastasis. Tumor cells expressing CD97 have been shown to
induce tumors in mice with greater vessel density than tumors derived from cells that didn’t
express CD97.31 In addition to CD97, three recently identified miR-126 targets also regulate
endothelial recruitment. Knockdown of genes encoding insulin-like growth factor binding
protein 2 (Igfbp2), c-Mer tyrosine kinase (Mertk), and phosphatidylinositol transfer protein
(Pitpnc1) significantly suppressed the ability of metastatic breast cancer cells to recruit
endothelial cells, leading to inhibition of metastatic colonization in vivo.32 The suppressive
role of miR-126 in non-cell-autonomous cancer progression is further illustrated by the
discovery that miR-126 also inhibits recruitment of mesenchymal stem cells and
inflammatory monocytes by targeting stromal cell-derived factor-1 alpha (Sdf-1α).21
miR-126 has been shown to regulate genes involved in both cell-autonomous and non-cell-
autonomous cancer progression (Figure 3). miR-126 can suppress cell-autonomous cancer
progression by targeting irs1 and crk to inhibit tumor cell proliferation, migration, and
invasion. miR-126 also inhibits metastasis in a non-cell autonomous manner by down-
regulating Igfbp2, Mertk, Pitpnc1, and Sdf-1α to limit cell recruitment. In addition, we now
know that miR-126 targets CD97, which has been shown to promote metastasis both by
stimulating tumor cell invasion and by inducing angiogenesis through recruitment of
endothelial cells. This discovery provides new insight into the mechanism of tumor
suppression by miR-126 and identifies a potential therapeutic target for controlling both
cell-autonomous and non-cell autonomous cancer progression.
Methods
Methods for creating transduced cell lines, FACS analysis, quantifying miR-126 expression,
mass spectrometry analysis, and luciferase assays are provided in the Supporting
Information.
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Figure 1. Quantitative, time-resolved proteomic analysis of miR-126 over-expression by
combining BONCAT and SILAC
Cells were cultured in SILAC medium containing either L-lysine (light) or [13C6, 15N2]L-
lysine (heavy, lys8) for five doubling times prior to induction of miR-126 expression for 24
h, followed by a 4 h Aha pulse. Lysates from the two cultures were mixed at equal protein
concentrations and conjugated to an alkyne-biotin tag. Newly synthesized proteins were
enriched prior to mass spectrometry analysis.
Lu et al. Page 8
ACS Chem Biol. Author manuscript; available in PMC 2015 February 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. miR-126 regulates cd97 by directly targeting its 3’-UTR
(a) pMIR-REPORT™ constructs used for the luciferase assay. Specific miRNA binding in
the 3’-UTR (untranslated region) should suppress reporter expression. (b) Human
embryonic kidney (HEK293) cells were co-transfected with pMIR-REPORT™ carrying the
indicated 3’-UTRs and pcDNA3.1™(+)-miR126 (miR-126) or pcDNA3.1™(+) (empty
vector control). Relative luciferase activity for the construct bearing the cd97 3’-UTR
decreased by 40% upon expression of miR-126, indicating that cd97 is a direct target of
miR126. 2miR contains two miR-126 binding sites; Irs1 is a known target of miR-126. (c)
Predicted miR-126 interaction sites in the cd97 3’-UTR and in cd97 3’-UTR mutants. (d)
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Either removing the predicted binding site or mutating three nucleotides within the binding
site abolished miR-126-dependent suppression of the luciferase activity of the cd97 3’-UTR
construct, confirming the miR-126 binding site within the cd97 3’-UTR. Mutations at a
random site within the cd97 3’-UTR had no effect on suppression of luciferase activity.
miR-ex control was taken as 100%. (e) The most favorable miR-126* interaction site in the
cd97 3’-UTR as predicted by RNAhybrid algorithm, and the cd97 3’-UTR mutant used for
luciferase assay. (f) Neither mutations at the predicted binding site for miR-126* nor at any
other random position within the cd97 3’-UTR reversed suppression of luciferase activity,
suggesting that miR-126* does not target the cd97 3’-UTR. miR-ex control was taken as
100%. P values were obtained using one-sided Student’s t-tests. *P < 0.01.
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Figure 3. Direct targets of miR-126 in cancer
CD97, a pro-metastatic GPCR, has been reported to promote tumor cell invasion cell-
autonomously by increasing tumor cell mobility and to induce angiogenesis non-cell-
autonomously by recruiting endothelial cells. The identification of CD97 as a direct target of
miR-126 sheds new light on the tumor suppressive roles of miR-126 in both cell-
autonomous and non-cell-autonomous cancer progression.
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